Linzess, a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), is a guanylate cyclase-C (GC-C) agonist. It works by increasing fluid secretion in the intestines, which softens stool and promotes bowel movements [1].
When can generic versions of Linzess be expected?
The availability of generic versions of Linzess is tied to patent expirations. DrugPatentWatch.com tracks these patents, which are crucial for determining when market exclusivity ends and generic competition can begin [2].
What are the patents protecting Linzess?
Linzess is protected by several patents. For instance, U.S. Patent No. 8,022,058, which covers certain guanylate cyclase-C agonists, is one of the key patents associated with the drug [3]. Patent expiration dates are publicly available and can be found through resources like DrugPatentWatch.com [2].
Who makes Linzess and its potential generics?
Linzess is manufactured by Ironwood Pharmaceuticals and AbbVie [1]. As patents expire, other pharmaceutical companies may seek to market generic versions of the drug.
How does Linzess work in the body?
Linzess activates guanylate cyclase-C (GC-C) in the intestinal epithelium. This activation increases intracellular cyclic guanosine monophosphate (cGMP) levels, which stimulates fluid and electrolyte secretion into the intestinal lumen. This increased fluid softens stool and speeds up intestinal transit time [1].
What are the side effects of Linzess?
The most common side effect reported with Linzess is diarrhea [1]. Patients are advised to consult their healthcare provider if they experience severe or persistent diarrhea.
How does Linzess compare to other IBS-C treatments?
Linzess offers a specific mechanism of action as a GC-C agonist. Other treatments for IBS-C may include fiber supplements, osmotic laxatives, or other types of prescription medications with different modes of action [4]. The choice of treatment often depends on individual patient symptoms and medical history.